GlassScriptPhysician profile
Todd Andrew Levin
NPI 1487623989
$64,284.95
in general payments reported to CMS, 2019-2025
41 companies · $4,939 in 2025
The $4,939 reported for 2025 was more than what 84% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,270 · 2020: $6,468 · 2021: $18K · 2022: $4,236 · 2023: $12K · 2024: $12K · 2025: $4,939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Food and Beverage: $6,687 · Education: $76.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,575.00 |
| Food and Beverage | $6,687.40 |
| Education | $76.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $40,084.33 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Pfizer INC. | $6,596.99 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $5,147.79 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $3,699.96 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,276.53 | 2019-2025 | Dupixent |
| Csl Behring | $918.38 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $895.75 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Genzyme Corporation | $775.89 | 2020-2025 | |
| Grifols USA, LLC | $593.55 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Genentech USA, INC. | $522.59 | 2019-2025 | Xolair |
| Optinose US, INC. | $469.33 | 2020-2025 | |
| Covis Pharma Gmbh | $435.18 | 2019-2023 | |
| Pharming Healthcare, INC. | $341.33 | 2021-2025 | Ruconest |
| Abbvie INC. | $322.44 | 2021-2024 | |
| Amgen INC. | $289.82 | 2022-2025 | Tezspire |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.